Alhumrani, S., Jamalludeen, N., Abdulhameed, A. (2020). Study of Interleukin 6 as marker of inflammation and a predictor of in-hospital complications in patients with acute coronary syndrome. , 38(2), 115-119. doi: 10.33762/mjbu.2020.128197.1032
Sally Abdul-Raheem Alhumrani; Nidham Mohammed Jamalludeen; Abdulameer Abdulbari Abdulhameed. "Study of Interleukin 6 as marker of inflammation and a predictor of in-hospital complications in patients with acute coronary syndrome". , 38, 2, 2020, 115-119. doi: 10.33762/mjbu.2020.128197.1032
Alhumrani, S., Jamalludeen, N., Abdulhameed, A. (2020). 'Study of Interleukin 6 as marker of inflammation and a predictor of in-hospital complications in patients with acute coronary syndrome', , 38(2), pp. 115-119. doi: 10.33762/mjbu.2020.128197.1032
Alhumrani, S., Jamalludeen, N., Abdulhameed, A. Study of Interleukin 6 as marker of inflammation and a predictor of in-hospital complications in patients with acute coronary syndrome. , 2020; 38(2): 115-119. doi: 10.33762/mjbu.2020.128197.1032
Study of Interleukin 6 as marker of inflammation and a predictor of in-hospital complications in patients with acute coronary syndrome
1Dept. of Microbiology College of Medicine University of Basrah
2Department of Microbiology, College of Medicine, University of Basrah, Basrah, Iraq
3Department of Medicine College of Medicine University of Basrah Basrah, Iraq
Abstract
Abstract: Background Although abnormal fatty deposits of infected arterial plaque play a major role in the formation of atherosclerotic plaque, activation of inflammatory cells plays a major role in the instability of the plaque and the cause of acute coronary syndrome. The aim of this study was to measure the level of interleukin-6 and to study its association with complications that occur in hospital in patients with acute coronary syndrome. Method: One hundred and twenty-five patients with acute coronary syndrome and 120 healthy individuals as a control group were included in this study. According to ECG and serum troponin changes, the patient group was classified into three ST-elevated myocardial infarction, ST non-elevated myocardial infarction and unstable angina. Sandwich ELISA was used by commercial groups (LEGAND MAX TM) for the IL-6 assay. Result: This study shows significantly significant differences in the level of IL-6 in patients with acute coronary syndrome (73.37 pg / dL) compared to the control group (9.47 pg / dL) (P value 0.001) There were no significant differences at the level of IL-6 in patients with acute coronary syndrome and conventional risk factors (P. value <0.05). There were significant differences in the level of IL-6 in all forms of ACS. (P. value 0.001). And those patients who had complications in hospital had a higher IL-6 level (92.89 Pg / dl) than those without complications (68.83 Pg / dl) P. value (0.012). Conclusion: This study indicated that IL-6 was significantly elevated in ACS patients